Vanucizumab, referred to as VPC-600, represents a cutting-edge monoclonal compound specifically targeting vascular endothelial growth factor VEGF-A. This potent agent functions by binding to VEGF-A, effectively preventing its linkage with its receptors and subsequently lessening angiogenesis—the